This is in line with a previous study revealing that BIM determines ABT-737 sensitivity of small cell lung cancer cells with low NOXA expression [57] and with our data that ABT-737 in combination with sorafenib induces cell death in Hep3B cells that lack NOXA but reveal BIM expression. This evidence concerns the gene BCL2L11 and small cell lung carcinoma.